Evidence map›Paper›PMID 30147278›Full record

ArticleTrends in cancer research2017

How does inflammation drive mutagenesis in colorectal cancer?

Chia Wei Hsu, Mark L Sowers, Willie Hsu, Eduardo Eyzaguirre, Suimin Qiu, Celia Chao, Charles P Mouton, Yuri Fofanov, Pomila Singh, Lawrence C Sowers

Open access · greenAbstract read
In one paragraph

Article in Trends in cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Oncology reviews · 2021
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Chia Wei HsuMD/PhD program, University of Texas Medical Branch, Galveston, Texas.
Mark L SowersMD/PhD program, University of Texas Medical Branch, Galveston, Texas.
Willie HsuDepartment of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas.
Eduardo EyzaguirreDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas.
Suimin QiuDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas.
Celia ChaoDepartment of Surgery, University of Texas Medical Branch, Galveston, Texas.
Charles P MoutonDepartment of Family Medicine, University of Texas Medical Branch, Galveston, Texas.
Yuri FofanovDepartment of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas.
Pomila SinghDepartment of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, Texas.
Lawrence C SowersDepartment of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas.
The University of Texas Medical Branch at Galveston · US

Funding

Role of Annexin-II in growth factor/co-carcinogenic effects of progastrinR01CA097959 · NCI · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI SINGH, POMILA · 2003 to 2015
$3.7M
INFIDELITY OF CYTOSINE METHYLATION AND HUMAN CANCERR01CA084487 · NCI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI SOWERS, LAWRENCE C · 2000 to 2016
$3.6M
NCI NIH HHS R01 CA084487NCI NIH HHS R01 CA097959
6 · The paper itself

Abstract

Colorectal cancer (CRC) is a major health challenge worldwide. Factors thought to be important in CRC etiology include diet, microbiome, exercise, obesity, a history of colon inflammation and family history. Interventions, including the use of non-steroidal anti-Inflammatory drugs (NSAIDs) and anti-inflammatory agents, have been shown to decrease incidence in some settings. However, our current understanding of the mechanistic details that drive CRC are insufficient to sort out the complex and interacting factors responsible for cancer-initiating events. It has been known for some time that the development of CRC involves mutations in key genes such as p53 and APC, and the sequence in which these mutations occur can determine tumor presentation. Observed recurrent mutations are dominated by C to T transitions at CpG sites, implicating the deamination of 5-methylcytosine (5mC) as a key initiating event in cancer-driving mutations. While it has been widely assumed that inflammation-mediated oxidation drives mutations in CRC, oxidative damage to DNA induces primarily G to T transversions, not C to T transitions. In this review, we discuss this unresolved conundrum, and specifically, we elucidate how the known nucleotide excision repair (NER) and base excision repair (BER) pathways, which are partially redundant and potentially competing, might provide a critical link between oxidative DNA damage and C to T mutations. Studies using recently developed next-generation DNA sequencing technologies have revealed the genetic heterogeneity in human tissues including tumors, as well as the presence of DNA damage. The capacity to follow DNA damage, repair and mutagenesis in human tissues using these emerging technologies could provide a mechanistic basis for understanding the role of oxidative damage in CRC tumor initiation. The application of these technologies could identify mechanism-based biomarkers useful in earlier diagnosis and aid in the development of cancer prevention strategies.

Indexed as

base excision repaircolorectal cancerdeaminationDNA repairinflammationmutationsoxidation

Identifiers

PMID30147278
PMCPMC6107301
OpenAlexW2991034851

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.